CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

Thomas J. Montine, Min Shi, Joseph F. Quinn, Elaine R. Peskind, Suzanne Craft, Carmen Ginghina, Kathryn A. Chung, Hojoong Kim, Douglas R. Galasko, Joseph Jankovic, Cyrus P. Zabetian, James B. Leverenz, Jing Zhang

Research output: Contribution to journalArticlepeer-review

153 Scopus citations


We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.

Original languageEnglish (US)
Pages (from-to)2682-2685
Number of pages4
JournalMovement Disorders
Issue number15
StatePublished - Nov 2010


  • CSF biomarkers
  • Cognitive impairment
  • Parkinson's disease
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'CSF Aβ42 and tau in Parkinson's disease with cognitive impairment'. Together they form a unique fingerprint.

Cite this